{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:26Z","timestamp":1793386466761,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28918","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T11:57:24Z","timestamp":1711972644000},"page":"e28918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"given":"Yue","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikai","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-9946","authenticated-orcid":false,"given":"Xiaohong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e28918_bib1","first-page":"11","article-title":"Pharmacology and neurochemistry of buspirone","volume":"43","author":"Riblet","year":"1982","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e28918_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3928\/02793695-20151022-01","article-title":"Buspirone: back to the future","volume":"53","author":"Howland","year":"2015","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"10.1016\/j.heliyon.2024.e28918_bib3","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.1097\/00004714-199006001-00013","article-title":"Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression","volume":"10","author":"Robinson","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00004714-199812000-00009","article-title":"Buspirone augmentation of antidepressant therapy","volume":"18","author":"Dimitriou","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4088\/JCP.v62n0608","article-title":"Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study","volume":"62","author":"Appelberg","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e28918_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jpsychires.2015.04.024","article-title":"Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder","volume":"68","author":"Targum","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.heliyon.2024.e28918_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.30773\/pi.2020.0017","article-title":"Efficacy of buspirone augmentation of escitalopram in patients with major depressive disorder with and without atypical features: a randomized, 8 Week, multicenter, open-label clinical trial","volume":"17","author":"Shin","year":"2020","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.heliyon.2024.e28918_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2020.10.020","article-title":"A trial of buspirone for anxiety in Parkinson's disease: safety and tolerability","volume":"81","author":"Schneider","year":"2020","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.heliyon.2024.e28918_bib9","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/apt.17479","article-title":"Buspirone for early satiety and symptoms of gastroparesis: a multi-centre, randomised, placebo-controlled, double-masked trial (BESST)","volume":"57","author":"Parkman","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28918_bib10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cgh.2012.06.036","article-title":"Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia","volume":"10","author":"Tack","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/apt.17511","article-title":"Editorial: buspirone for gastroparesis-an intriguing option for a challenging condition","volume":"57","author":"Sayuk","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28918_bib12","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1136\/gutjnl-2019-318712","article-title":"Gastroparesis: a turning point in understanding and treatment","volume":"68","author":"Grover","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.heliyon.2024.e28918_bib13","first-page":"100","article-title":"The side effect profile of buspirone in comparison to active controls and placebo","volume":"43","author":"Newton","year":"1982","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e28918_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9343(86)90327-X","article-title":"Review of the side-effect profile of buspirone","volume":"80","author":"Newton","year":"1986","journal-title":"Am. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28918_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/bs.pbr.2022.01.013","article-title":"Cognition and serotonin in Parkinson's disease","volume":"269","author":"Frouni","year":"2022","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.heliyon.2024.e28918_bib16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00019442-200508000-00007","article-title":"Effects of anxiety versus depression on cognition in later life","volume":"13","author":"Bierman","year":"2005","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e28918_bib17","doi-asserted-by":"crossref","first-page":"P246","DOI":"10.1093\/geronb\/57.3.P246","article-title":"Anxiety, cognitive performance, and cognitive decline in normal aging","volume":"57","author":"Wetherell","year":"2002","journal-title":"J. Gerontol. B Psychol. Sci. Soc. Sci."},{"key":"10.1016\/j.heliyon.2024.e28918_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1176\/ajp.150.3.429","article-title":"Aging, emotional states, and memory","volume":"150","author":"Deptula","year":"1993","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e28918_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.heliyon.2024.e28918_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00406-006-0704-0","article-title":"Disorganization and cognitive impairment in schizophrenia: independent symptom dimensions?","volume":"256","author":"Klingberg","year":"2006","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e28918_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oxfordjournals.schbul.a033380","article-title":"Should schizophrenia be treated as a neurocognitive disorder?","volume":"25","author":"Green","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.heliyon.2024.e28918_bib22","series-title":"Chinese Guidelines for the Prevention and Treatment of Schizo- Phrenia","author":"Zhao","year":"2015"},{"key":"10.1016\/j.heliyon.2024.e28918_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/jamapsychiatry.2014.2476","article-title":"Amyloid-beta, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study","volume":"72","author":"Pietrzak","year":"2015","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e28918_bib24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1532-5415.2011.03521.x","article-title":"Anxiety, depression, and 1-year incident cognitive impairment in community-dwelling older adults","volume":"59","author":"Potvin","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.heliyon.2024.e28918_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40035-023-00381-x","article-title":"NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors","volume":"12","author":"Xu","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.heliyon.2024.e28918_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e28918_bib27","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2024.e28918_bib28","doi-asserted-by":"crossref","first-page":"e1631","DOI":"10.4088\/JCP.15m10413","article-title":"Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer's disease","volume":"77","author":"Cavedo","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e28918_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/157015910790909520","article-title":"Update on the pharmacological treatment of Alzheimer's disease","volume":"8","author":"Massoud","year":"2010","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib30","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.heliyon.2024.e28918_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/00131746-200311000-00005","article-title":"The cholinesterase inhibitors","volume":"9","author":"Rubey","year":"2003","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.heliyon.2024.e28918_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40266-015-0266-9","article-title":"A risk-benefit assessment of dementia medications: systematic review of the evidence","volume":"32","author":"Buckley","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.heliyon.2024.e28918_bib33","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1111\/bph.15920","article-title":"Chondroitin sulfate proteoglycan is a potential target of memantine to improve cognitive function via the promotion of adult neurogenesis","volume":"179","author":"Maeda","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2019.05.006","article-title":"Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia","volume":"209","author":"Wang","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.heliyon.2024.e28918_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbr.2015.03.025","article-title":"The serotonin 5-HT(1)A receptor agonist tandospirone improves executive function in common marmosets","volume":"287","author":"Baba","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.heliyon.2024.e28918_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","article-title":"Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"95","author":"Sumiyoshi","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.heliyon.2024.e28918_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40120-013-0015-0","article-title":"Chronic treatment with the 5-HT1A receptor partial agonist tandospirone increases hippocampal neurogenesis","volume":"3","author":"Mori","year":"2014","journal-title":"Neurol Ther."},{"key":"10.1016\/j.heliyon.2024.e28918_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yrtph.2018.09.017","article-title":"Dose related effects of buspirone on pain, learning\/memory and food intake","volume":"99","author":"Haleem","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib39","first-page":"103","article-title":"A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder","volume":"43","author":"Feighner","year":"1982","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e28918_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nlm.2013.12.015","article-title":"Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation","volume":"110","author":"Schreiber","year":"2014","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.heliyon.2024.e28918_bib41","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3389\/fphar.2017.00710","article-title":"Buspirone counteracts MK-801-induced schizophrenia-like phenotypes through dopamine D(3) receptor blockade","volume":"8","author":"Torrisi","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e28918_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e28918_bib44","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 8: assessing risk of bias in a randomized trial","author":"Higgins","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e28918_bib45","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e28918_bib46","doi-asserted-by":"crossref","first-page":"302","DOI":"10.34172\/mejdd.2021.239","article-title":"Effectiveness of buspirone in patients with functional dyspepsia: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Taghvaei","year":"2021","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.heliyon.2024.e28918_bib47","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1365-2036.2008.03849.x","article-title":"Influence of buspirone on gastric sensorimotor function in man","volume":"28","author":"Van Oudenhove","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28918_bib48","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0149-2918(03)80159-5","article-title":"A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone","volume":"25","author":"Robinson","year":"2003","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.heliyon.2024.e28918_bib49","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00213-004-2111-4","article-title":"Dizziness produced by a potent 5HT(1A) receptor agonist (eptapirone) is not due to postural hypotension","volume":"179","author":"Wilson","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.heliyon.2024.e28918_bib50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/ijnp\/pyad004","article-title":"Effect of 5-ht1a receptor partial agonists of the azapirone class as an add-on therapy on psychopathology and cognition in schizophrenia: a systematic review and meta-analysis","volume":"26","author":"Yamada","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.heliyon.2024.e28918_bib51","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jnc.12512","article-title":"Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism","volume":"128","author":"Huang","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.heliyon.2024.e28918_bib52","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/npp.2014.51","article-title":"Dopamine D3 receptor is necessary for ethanol consumption: an approach with buspirone","volume":"39","author":"Leggio","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.heliyon.2024.e28918_bib53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D(3) receptor neurotransmission in cognition","volume":"23","author":"Nakajima","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.heliyon.2024.e28918_bib54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3389\/fnbeh.2014.00291","article-title":"Tandospirone, a 5-HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N-methy-D-aspartate receptors; toward the therapeutics of cognitive impairment of schizophrenia","volume":"8","author":"Uehara","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e28918_bib55","article-title":"Augmentation therapy with serotonin(1A) receptor partial agonists on neurocognitive function in schizophrenia: a systematic review and meta-analysis","volume":"34","author":"Yamada","year":"2023","journal-title":"Schizophr Res Cogn."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024049491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024049491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:59:40Z","timestamp":1784206780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024049491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024049491"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28918","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28918"}}